This company has been acquired
Paratek Pharmaceuticals Crecimiento futuro
Future controles de criterios 4/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Paratek Pharmaceuticals.
Información clave
73.2%
Tasa de crecimiento de los beneficios
72.9%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Pharmaceuticals | 27.3% |
Tasa de crecimiento de los ingresos | 13.8% |
Rentabilidad financiera futura | n/a |
Cobertura de analistas | Low |
Última actualización | 07 Aug 2023 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Improved Revenues Required Before Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock's 77% Jump Looks Justified
Apr 17Paratek Pharmaceuticals: Patience Is Wearing Thin
Aug 24Paratek Pharmaceuticals GAAP EPS of -$0.33 beats by $0.01, revenue of $29.6M beats by $0.42M
Aug 03Paratek Pharmaceuticals: A Deeply Undervalued Antibiotic Company
Jan 03The Play On Paratek Pharmaceuticals
Oct 18Peeking Back In On Paratek Pharmaceuticals
Aug 07Paratek Pharma launches Phase 2b Nuzyra study in nontuberculous mycobacterial
Jun 16Paratek shares rise after FDA approves NUZYRA oral only dosing regimen
Jun 01Paratek Offers Long-Term Value Potential In The Difficult Antibiotic Business
Apr 27Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): Are Analysts Optimistic?
Mar 01Could The Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ownership Structure Tell Us Something Useful?
Feb 01Paratek Pharmaceuticals secures $60M non-recourse loan for Hercules debt repayment
Jan 04Paratek Pharmaceuticals: 100%+ Upside As Nuzyra Sales Scale
Dec 01Paratek Pharmaceuticals, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 06Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
12/31/2025 | 221 | 2 | -9 | N/A | 2 |
12/31/2024 | 218 | -14 | 30 | N/A | 3 |
12/31/2023 | 163 | -46 | -10 | N/A | 2 |
6/30/2023 | 177 | -63 | -23 | -23 | N/A |
3/31/2023 | 167 | -66 | -36 | -36 | N/A |
12/31/2022 | 160 | -64 | -66 | -66 | N/A |
9/30/2022 | 117 | -89 | -66 | -66 | N/A |
6/30/2022 | 111 | -86 | -27 | -27 | N/A |
3/31/2022 | 139 | -59 | -46 | -46 | N/A |
12/31/2021 | 130 | -59 | -49 | -48 | N/A |
9/30/2021 | 114 | -52 | -53 | -52 | N/A |
6/30/2021 | 104 | -54 | -108 | -107 | N/A |
3/31/2021 | 55 | -87 | -95 | -95 | N/A |
12/31/2020 | 47 | -97 | -104 | -103 | N/A |
9/30/2020 | 40 | -99 | -116 | -115 | N/A |
6/30/2020 | 30 | -111 | -115 | -114 | N/A |
3/31/2020 | 23 | -121 | -129 | -129 | N/A |
12/31/2019 | 17 | -129 | -134 | -134 | N/A |
9/30/2019 | 25 | -124 | -118 | -117 | N/A |
6/30/2019 | 21 | -124 | -110 | -110 | N/A |
3/31/2019 | 19 | -120 | -98 | -98 | N/A |
12/31/2018 | 17 | -112 | -81 | -81 | N/A |
9/30/2018 | 5 | -111 | -85 | -85 | N/A |
6/30/2018 | 5 | -101 | -80 | -80 | N/A |
3/31/2018 | 13 | -89 | -73 | -73 | N/A |
12/31/2017 | 13 | -89 | -80 | -79 | N/A |
9/30/2017 | 8 | -94 | -82 | -80 | N/A |
6/30/2017 | 8 | -96 | -95 | -94 | N/A |
3/31/2017 | 0 | -108 | N/A | -101 | N/A |
12/31/2016 | 0 | -112 | N/A | -94 | N/A |
9/30/2016 | N/A | -106 | N/A | -86 | N/A |
6/30/2016 | N/A | -106 | N/A | -78 | N/A |
3/31/2016 | N/A | -91 | N/A | -70 | N/A |
12/31/2015 | N/A | -71 | N/A | -55 | N/A |
9/30/2015 | 4 | -61 | N/A | -49 | N/A |
6/30/2015 | 4 | -42 | N/A | -30 | N/A |
3/31/2015 | 4 | -29 | N/A | -18 | N/A |
12/31/2014 | 4 | -20 | N/A | -19 | N/A |
9/30/2014 | 0 | -12 | N/A | -9 | N/A |
6/30/2014 | 1 | -11 | N/A | -8 | N/A |
3/31/2014 | 0 | -11 | N/A | -8 | N/A |
12/31/2013 | 0 | -11 | N/A | -6 | N/A |
9/30/2013 | 1 | -37 | N/A | -9 | N/A |
6/30/2013 | 1 | -41 | N/A | -11 | N/A |
3/31/2013 | 3 | -45 | N/A | -10 | N/A |
12/31/2012 | 3 | -50 | N/A | -12 | N/A |
9/30/2012 | 4 | -28 | N/A | -12 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: PRTK is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Beneficios vs. Mercado: PRTK is forecast to become profitable over the next 3 years, which is considered above average market growth.
Beneficios de alto crecimiento: PRTK is expected to become profitable in the next 3 years.
Ingresos vs. Mercado: PRTK's revenue (13.8% per year) is forecast to grow faster than the US market (7.7% per year).
Ingresos de alto crecimiento: PRTK's revenue (13.8% per year) is forecast to grow slower than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if PRTK's Return on Equity is forecast to be high in 3 years time